Association of IL-6 and TNF-α with mortality in hospitalized cancer patients

Reliable prognostic biomarkers are needed to predict outcomes in hospitalized cancer patients with rash. Hospitalized cancer patients with rash and elevated IL-6 and TNF-α levels have a nearly 6 times decreased overall survival. Given the availability of TNF-α and IL-6 inhibitors, these biomarkers m...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 84; no. 2; pp. 273 - 282
Main Authors Stoll, Joseph R., Vaidya, Toral S., Mori, Shoko, Dusza, Stephen W., Lacouture, Mario E., Markova, Alina
Format Journal Article
LanguageEnglish
Published 12.03.2020
Online AccessGet full text

Cover

More Information
Summary:Reliable prognostic biomarkers are needed to predict outcomes in hospitalized cancer patients with rash. Hospitalized cancer patients with rash and elevated IL-6 and TNF-α levels have a nearly 6 times decreased overall survival. Given the availability of TNF-α and IL-6 inhibitors, these biomarkers may serve as potential therapeutic targets.
Bibliography:Joseph R. Stoll, BTL (1), (2), (3)
Mario E. Lacouture, MD: (1), (2), (3)
Alina Markova, MD: (1), (2), (3)
Authorship contributions
(2) Drafting and revising the article for important intellectual content
Stephen W. Dusza, DrPH: (1), (2), (3)
(1) Acquisition, analysis and interpretation of data
Shoko Mori, BS: (1), (2), (3)
Toral S. Vaidya, MPH (1), (2), (3)
(3) Final approval of the version to be submitted
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2020.03.010